NASDAQ:CHMAChiasma Stock Price, Forecast & News

Chiasma's stock was trading at $3.92 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CHMA stock has increased by 73.7% and is now trading at $6.81. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chiasma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Chiasma.

Chiasma is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Chiasma.

Chiasma Inc (NASDAQ:CHMA) released its earnings results on Thursday, May, 7th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.05. View Chiasma's earnings history.

5 brokers have issued 12-month price objectives for Chiasma's shares. Their forecasts range from $10.00 to $18.00. On average, they expect Chiasma's share price to reach $13.00 in the next twelve months. This suggests a possible upside of 90.9% from the stock's current price. View analysts' price targets for Chiasma.

News articles about CHMA stock have been trending somewhat positive recently, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Chiasma earned a news sentiment score of 1.5 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutChiasma.

Chiasma saw a decline in short interest during the month of April. As of April 30th, there was short interest totaling 1,540,000 shares, a decline of 24.9% from the April 15th total of 2,050,000 shares. Based on an average trading volume of 325,100 shares, the days-to-cover ratio is currently 4.7 days. Currently, 5.0% of the shares of the stock are sold short. View Chiasma's Current Options Chain.

Some companies that are related to Chiasma include Myovant Sciences (MYOV), I-Mab (ARQT), Enanta Pharmaceuticals (ENTA), Aimmune Therapeutics (AIMT), Rocket Pharmaceuticals (RCKT), Applied Therapeutics (APLT), Phibro Animal Health (PAHC), Odonate Therapeutics (ODT), BioXcel Therapeutics (BTAI), Stoke Therapeutics (STOK), NextCure (NXTC), Athenex (ATNX), ImmunoGen (IMGN), Rhythm Pharmaceuticals (RYTM) and Endo International (ENDP). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chiasma investors own include Arbutus Biopharma (ABUS), Bausch Health Companies (BHC), GW Pharmaceuticals PLC- (GWPH), BioDelivery Sciences International (BDSI), Viking Therapeutics (VKTX), Alnylam Pharmaceuticals (ALNY), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Exelixis (EXEL) and Progenics Pharmaceuticals (PGNX).

(CHMA) raised $76 million in an initial public offering (IPO) on Thursday, July 16th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. Barclays and Cowen and Company served as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

Chiasma trades on the NASDAQ under the ticker symbol "CHMA."

Chiasma's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.04%), Ikarian Capital LLC (4.91%), Rock Springs Capital Management LP (3.19%), Vivo Capital LLC (3.01%), Stonepine Capital Management LLC (1.76%) and State Street Corp (1.47%). Company insiders that own Chiasma stock include Mark J Fitzpatrick, Roni Mamluk, Scott Minick and William Ludlam. View institutional ownership trends for Chiasma.

CHMA stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, WINTON GROUP Ltd, JPMorgan Chase & Co., UBS Group AG, and Deutsche Bank AG. View insider buying and selling activity for Chiasma.

CHMA stock was acquired by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Ikarian Capital LLC, Stonepine Capital Management LLC, Rock Springs Capital Management LP, Geode Capital Management LLC, Los Angeles Capital Management & Equity Research Inc., Spark Investment Management LLC, and BlackRock Inc.. Company insiders that have bought Chiasma stock in the last two years include Mark J Fitzpatrick, Scott Minick, and William Ludlam. View insider buying and selling activity for Chiasma.

Shares of CHMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CHMA stock can currently be purchased for approximately $6.81.

Chiasma has a market capitalization of $287.79 million. The biotechnology company earns $-36,320,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. Chiasma employs 49 workers across the globe.

The official website for Chiasma is www.chiasmapharma.com.

Chiasma's mailing address is 140 Kendrick Street Building C East, Needham MA, 02494. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected]